Prometheus Biosciences (United States)

Recent papers from Prometheus Biosciences (United States)

1. Deciphering the prodrome of inflammatory bowel disease up to 10 years before disease onset by massively parallel serologyGut · 2026
2. The Association Between 6-Thioguanine Nucleotide Levels, Adalimumab Exposure, Immune Response, and Drug ClearanceCrohn s & Colitis 360 · 2026
3. Abstract 4416: Overcoming the limited monospecific target landscape in cancer via discovery of tumor selective AND and OR gate bispecificsCancer Research · 2026
4. Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel diseaseEuropean Journal of Gastroenterology & Hepatology · 2026
5. Determination of correlation of clearance with clinical outcomes for inflammatory bowel diseaseWorld Journal of Gastroenterology · 2026
6. Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational studyFrontiers in Immunology · 2026
7. DOP017Unique serological signatures enable the diagnosis and stratification of Inflammatory Bowel DiseaseJournal of Crohn s and Colitis · 2026
8. Impact of Precision-Guided Dosing on Clinical Decision-Making and Health Care Utilization in Inflammatory Bowel Disease: A Retrospective Pretest/Posttest Real-World StudyCrohn s & Colitis 360 · 2025
9. The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience ProgramPharmaceutics · 2025
10. Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel DiseasePharmaceutics · 2025
11. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulationNature Communications · 2024
12. Neutralizing Antibody Sample Testing and Report HarmonizationThe AAPS Journal · 2024
13. Simulated cost‐effectiveness of a novel precision‐guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapyPharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
14. Nutritional Biomarkers for the Prediction of Response to Anti-TNF-α Therapy in Crohn’s Disease: New Tools for New ApproachesNutrients · 2024
15. Older Adults With Inflammatory Bowel Disease Are at Higher Risk of Developing Antibodies to InfliximabInflammatory Bowel Diseases · 2024
16. Anti‐infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel diseaseJournal of Pediatric Gastroenterology and Nutrition · 2023
17. The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with InfliximabPharmaceutics · 2023
18. Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative ColitisThe American Journal of Gastroenterology · 2023
19. The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control During Treatment of Pediatric Crohn’s Disease with Infliximab2023
20. A Novel 8-Predictors Signature to Predict Complicated Disease Course in Pediatric-onset Crohn’s Disease: A Population-based StudyInflammatory Bowel Diseases · 2023